Establishment Labs (NASDAQ:ESTA) Given "Overweight" Rating at Stephens

Establishment Labs (NASDAQ:ESTA - Get Free Report)'s stock had its "overweight" rating reiterated by Stephens in a research report issued on Thursday,Benzinga reports. They currently have a $52.00 price objective on the stock. Stephens' price target points to a potential upside of 21.27% from the company's current price.

Establishment Labs Trading Up 0.0 %

Shares of ESTA stock traded up $0.01 during trading hours on Thursday, hitting $42.88. 837,175 shares of the company's stock traded hands, compared to its average volume of 688,242. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. Establishment Labs has a 12 month low of $28.16 and a 12 month high of $60.12. The stock has a market cap of $1.20 billion, a PE ratio of -16.62 and a beta of 1.12. The stock's 50 day simple moving average is $37.50 and its 200 day simple moving average is $41.34.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The company had revenue of $44.51 million for the quarter, compared to the consensus estimate of $44.45 million. On average, sell-side analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ESTA. Brown Advisory Inc. boosted its stake in shares of Establishment Labs by 23.1% in the 4th quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock valued at $107,729,000 after purchasing an additional 438,057 shares during the last quarter. Capital Research Global Investors lifted its holdings in Establishment Labs by 29.3% in the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock valued at $88,064,000 after buying an additional 433,484 shares during the period. Findell Capital Management LLC boosted its position in Establishment Labs by 28.5% during the fourth quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock valued at $62,032,000 after acquiring an additional 298,380 shares during the last quarter. William Blair Investment Management LLC grew its holdings in Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock worth $37,447,000 after acquiring an additional 248,888 shares during the period. Finally, Rice Hall James & Associates LLC raised its position in shares of Establishment Labs by 10.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company's stock worth $34,326,000 after acquiring an additional 76,959 shares in the last quarter. Institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.